Target type: biologicalprocess
A heterochromatin formation-based gene silencing process mediated by a regulatory non-coding RNA molecule that occur before the beginnning of trancription. [PMID:19239886, PMID:21420348]
Regulatory non-coding RNAs (ncRNAs) play a crucial role in heterochromatin formation, a process that involves the packaging of DNA into a tightly condensed state. Heterochromatin is generally transcriptionally inactive and is essential for maintaining genome stability, regulating gene expression, and controlling chromosome structure.
ncRNAs can contribute to heterochromatin formation through various mechanisms:
1. **Recruitment of chromatin modifying enzymes:** Some ncRNAs directly interact with proteins that modify chromatin structure, such as histone methyltransferases (HMTs), histone deacetylases (HDACs), and DNA methyltransferases (DNMTs). These enzymes can catalyze specific modifications on histones and DNA, respectively, which are characteristic of heterochromatin. For example, the ncRNA Xist is crucial for X chromosome inactivation in mammals. It recruits the PRC2 complex, a histone methyltransferase, to the inactive X chromosome, leading to the methylation of histone H3 at lysine 27 (H3K27me3), a hallmark of heterochromatin.
2. **Scaffolding for chromatin complexes:** ncRNAs can act as scaffolds, bringing together multiple proteins involved in heterochromatin formation. This can facilitate the assembly of large protein complexes that modify chromatin structure and repress gene expression. For instance, the ncRNA HOTAIR interacts with both the PRC2 and LSD1 complexes, bringing them to specific genomic regions and promoting the formation of repressive heterochromatin.
3. **Direct interaction with DNA:** Some ncRNAs can bind directly to DNA, influencing the accessibility of the DNA to transcription factors and other regulatory proteins. This interaction can stabilize or destabilize chromatin structure, depending on the specific ncRNA and its target DNA sequence.
4. **Regulation of chromatin remodelers:** ncRNAs can regulate the activity of chromatin remodelers, enzymes that alter the position of nucleosomes on DNA. This can affect the accessibility of DNA to transcription factors and other regulatory proteins, ultimately influencing heterochromatin formation.
5. **Inducing DNA methylation:** Some ncRNAs can trigger DNA methylation, a key modification associated with heterochromatin. This can lead to the silencing of genes and the establishment of heterochromatin domains.
The specific ncRNAs involved in heterochromatin formation vary depending on the organism and the specific genomic region being targeted. However, the general mechanisms described above provide a framework for understanding how ncRNAs contribute to this fundamental process.
These mechanisms highlight the crucial role of ncRNAs in regulating gene expression, controlling genome organization, and maintaining genome stability. They also underscore the complexity and versatility of the ncRNA world, showcasing their diverse functions beyond protein coding.'
"
Protein | Definition | Taxonomy |
---|---|---|
DNA (cytosine-5)-methyltransferase 3A | A DNA (cytosine-5)-methyltransferase 3A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y6K1] | Homo sapiens (human) |
Histone-lysine N-methyltransferase EZH2 | A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
procainamide | procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. | benzamides | anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker |
dichlone | dichlone: structure | ||
5,5'-methylenedisalicylic acid | 5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934 | ||
3-deazaneplanocin | 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist | ||
tanshinone | tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent | abietane diterpenoid | anticoronaviral agent |
przewaquinone d | przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D | ||
tanshinone ii a | tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source | abietane diterpenoid | |
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
rg108 | RG108: DNA methyltransferase inhibitor; structure in first source | indolyl carboxylic acid | |
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
sgi-1027 | SGI-1027: inhibits DNA methyltransferase 1; structure in first source | ||
epz005687 | EPZ005687: inhibits EZH2 protein; structure in first source | indazoles | |
epz-6438 | tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity | ||
gsk-2816126 | GSK-2816126: inhibits EZH2 methyltransferase; structure in first source | piperazines; pyridines | |
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | (R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitor | indolecarboxamide |